PulseSelect Pulse Field Ablation (PFA) Catheter
Medtronic, Inc. · Decision date Apr 13, 2026
What did the FDA approve?
FDA records P230017/S010 as a supplement to PMA P230017, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Apr 13, 2026.
FDA approval order statement
approval for a manufacturing site located at Parkmore Business Park, West, Ballybrit, Galway, Ireland
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track No User Fee
- Clinical specialty
- Cardiovascular
- Decision date
- Apr 13, 2026
- FDA change category
- Location Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P230017/S010
- Regulatory pathway
- PMA supplement
- Applicant
- Medtronic, Inc.
- Product code
- QZI
- Decision code
- APPR
- Decision date
- Apr 13, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Percutaneous Cardiac Ablation Catheter for Treatment of Atrial Fibrillation with Irreversible Electroporation.
- Applicant
- Medtronic, Inc.
- Product code
- QZI
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P230017/S008 · Related supplement
PulseSelect Pulsed Field Ablation (PFA) system
P230017/S009 · Related supplement
PulseSelect Pulsed Field Ablation (PFA) system
P230017/S010 received
Application receipt date recorded by FDA.
P230017/S010 · FDA decision
Normal 180 Day Track No User Fee
P230017/S011 · Related supplement
PulseSelect Pulse Field Ablation (PFA) Catheter
Timeline entries are records held by MedtechLedger for P230017. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P230017
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
PulseSelect Pulsed Field Ablation (PFA) systemP230017/S008 | Medtronic, Inc. | PMA supplement | Oct 8, 2025 | FDA |
PulseSelect Pulsed Field Ablation (PFA) systemP230017/S009 | Medtronic, Inc. | PMA supplement | Feb 17, 2026 | FDA |
PulseSelect Pulse Field Ablation (PFA) CatheterP230017/S011 | Medtronic, Inc. | PMA supplement | Jun 30, 2026 | FDA |
Explore the linked device profile
Other records with product code QZI
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Varipulse Bi-Directional CatheterP240006/S018 | Biosense Webster, Inc. | PMA supplement | Nov 3, 2026 | FDA |
Globe Catheter and Globe Pulsed Field SystemP240044/S007 | Kardium, Inc. | PMA supplement | Oct 27, 2026 | FDA |
Globe Pulsed Field System; Globe CatheterP240044/S008 | Kardium, Inc. | PMA supplement | Oct 23, 2026 | FDA |
Volt PFA SystemP250022/S002 | ABBOTT MEDICAL | PMA supplement | Oct 15, 2026 | FDA |
Affera Sphere-9 Mapping and Ablation CatheterP240013/S032 | Medtronic, Inc. | PMA supplement | Oct 9, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Medtronic, Inc.
- Headquarters
- Not reported
- Brand website
- medtronic.com
- FDA applicant address
- 8200 Coral Sea St. N.E, Mounds View, MN, 55112
Sources and methodology
- Original FDA record: P230017/S010
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


